October 2026
42 articles-
Oct 5 · 09:51Market Watch
Vaxcyte’s 50.53% Surge Prices In a Vaccine Challenger
-
Oct 5 · 09:23Biotechnology Daily
Optogenetics Wins Nobel, but Clinical Proof Is Separate
-
Oct 5 · 08:47Market Watch
$14.0 Million Lilly Buy Leaves XLV’s Weights Unresolved
-
Oct 4 · 20:19Bio Business News
CSL's $1.6 Billion Drug Deal Deepens Its Kidney Push
-
Oct 4 · 15:59Biotechnology Daily
Medicare Drug Rule Cuts Savings, Covers Only Four Firms
-
Oct 4 · 14:50Market Watch
GRAIL’s 171% Rally Raises the Bar After FDA News
-
Oct 4 · 13:40World News
Trump’s $90 Medicare Payment Pledge Leaves Key Questions
-
Oct 4 · 12:30Biotechnology Daily
CMS Finalizes GLOBE With a Smaller Medicare Savings Outlook
-
Oct 4 · 11:21Bio Business News
Parakeet Health Raises $10 Million for AI Patient Outreach
-
Oct 4 · 09:51Biotechnology Daily
Boehringer’s 9.8% Weight-Loss Result Faces Rival Scrutiny
-
Oct 4 · 09:21Bio Business News
Sanofi Commits $1 Billion to Its Post-Dupixent Pipeline
-
Oct 4 · 08:46Market Watch
XPH’s Return Edge Shows the Limits of XBI’s Broader Reach
-
Oct 3 · 20:19Biotechnology Daily
Science Puts Menopause and Chronic Pain Under the Lens
-
Oct 3 · 17:49World News
NIH Awarded Its Full Grant Budget as Researchers Hit Delays
-
Oct 3 · 15:59Bio Business News
Kallyope Becomes TriGemX Bio With $94M Migraine Focus
-
Oct 3 · 14:49Market Watch
October Dividend Picks Put Cash Coverage Ahead of Yield
-
Oct 3 · 13:41Bio Business News
Hospital AI Billing Faces a $1 Billion Cost Challenge
-
Oct 3 · 12:30Bio Business News
Devoted Health Raises Nearly $1.2 Billion as Members Surge
-
Oct 3 · 11:21Market Watch
Pfizer and Energy Payouts Face a 5.3% Treasury Test
-
Oct 3 · 09:52Biotechnology Daily
Regeneron Muscle Recovery Data Look Beyond Wegovy Weight Loss
-
Oct 3 · 09:20Bio Business News
Sanofi, Regeneron Re-Up for $1B as Lilly Data Draw Focus
-
Oct 3 · 08:46Biotechnology Daily
Wegovy Pill Study Points to a Path Off Weekly Injections
-
Oct 2 · 20:25Bio Business News
Novartis Commits $575 Million to Abogen’s Early-Stage Asset
-
Oct 2 · 17:49Market Watch
Palvella's Oversold Flag Is Not Yet a Rebound Signal